We herein report a case study of a female newborn with multiple pituitary hormone deficiencies who presented with generalized seizures, hypoglycemia and hyperammonemia at 18 h after birth. In addition, we review the association of hyperammonemia in neonates with multiple pituitary hormone deficiencies reported in the previous literature. This unrecognized association should be taken into account for the early diagnosis and treatment of these patients.
Introduction
Congenital multiple pituitary hormone deficiency (MPHD) is a rare malformation in the midline of the brain, with an incidence of 1 in 100 000 live births. 1 Early diagnosis of MPHD in the absence of any obvious external malformations is often difficult during the neonatal period because of non-specific clinical presentation. Nevertheless, an early diagnosis is crucial, because severe hypoglycemia, and adrenal and thyroid insufficiencies may lead to catastrophic consequences for neurological development, and it could become life threatening. On the other hand, hyperammonemia in patients with MPHD during the neonatal period has rarely been documented. 2 In this paper, we describe a patient with congenital MPHD presenting transient hyperammonemia, and briefly review the previous reports of this unusual combination in the literature.
Case
A female infant of non-consanguineous parents was born at 37 weeks to a 36-year-old primagravida mother via uncomplicated vaginal delivery. The birth weight was 2680 g, and the infant's Apgar score was 9 at 1 min and 9 at 5 min. The infant started breast feeding soon after birth, but her sucking activity appeared to be insufficient. At 18 h of age, she presented with frequent apnea with general cyanosis, followed by generalized convulsions and was immediately transferred to the Neonatal Intensive Care Unit (NICU) in our hospital. At admission, she showed weak muscle tone, and her respiratory and circulatory statuses were normal. She showed no dysmorphic features. Rapid blood tests showed hypoglycemia (20 mg per 100 ml) and mild metabolic acidosis (pH 7.291; HCO 3 À 18.5 mmol l À1 ). She immediately received a bolus of 10% glucose solution, followed by a continuous infusion of 10% glucose solution. The following blood chemistry examination demonstrated that her ammonia level was high, at 262 mmol l À1 , suggesting the presence of an inborn error of metabolism. Other findings were as follows: total bilirubin 6.2 mg per 100 ml, conjugated bilirubin 0.7 mg per 100 ml, aspartate aminotransferase 72 U l À1 , alanine aminotransferase 8 U l À1 and insulin 1.7 IU ml À1 . Oral milk feeding was discontinued, and the infant was kept on a glucose infusion regimen to maintain her blood glucose level. The plasma amino-acid and fatty-acid metabolite analyses did not show any signs of an inborn error of metabolism. In addition, urine analysis by gas chromatography-mass spectrometry detected no specific metabolites. Cardiac and abdominal ultrasound scans did not detect any abnormalities. Brain computed tomography examination and cerebrospinal fluid analysis did not show any pathological findings.
The blood ammonia level gradually decreased to the normal level within 24 h, without any specific treatment for hyperammonemia. Then, oral feeding was restarted at 2 days of age. Nevertheless, the infant was lethargic, and she continued to exhibit poor feeding activity. Brain magnetic resonance imaging at 10 days of age showed no abnormality in the cerebral cortex or gray matter, whereas partial agenesis of corpus callosum was identified. Endocrinological investigation on day 15 was performed, and several abnormal parameters were detected as follows: cortisol 0.5 mg per 100 ml, adrenocorticotropic hormone 16.0 pg ml À1 , free triiodothyronine 2.56 pg ml À1 (normal range; 1.8 to 3.7), free thyroxine 0.92 ng per 100 ml (1.0 to 1.8), thyroid-stimulating hormone 8.88 mU ml À1 (1.9 to 9.1), growth hormone 6.64 ng ml À1 (5 to 27), insulin-like growth factor-1 34 ng ml À1 (15 to 108) and prolactin 126.4 ng ml À1 (6 to 14). The further investigation of the pituitary gland via magnetic resonance imaging demonstrated congenital pituitary hypoplasia and ectopic posterior pituitary gland without apparent optic nerve hypoplasia. An ophthalmological examination by fundoscopy did not reveal any abnormalities.
A regular dose of hydrocortisone (4 mg per day) and a minimal amount of thyroxine (5 mg per day) replacement therapy were started on days 15 and 17, respectively. We started thyroxine replacement therapy with low doses, because we were afraid thyroxine replacement might precipitate an acute adrenal crisis. After starting the hormone replacement, the infant's feeding activity markedly improved, and the prolonged jaundice without liver dysfunction was drastically recovered. We therefore diagnosed the patient to have MPHD. The dose of thyroxine was increased to 8 mg per day on day 25. Subsequently, serum cortisol and free thyroxine levels recovered to the normal range at 31 and 30 days of age, respectively. She was discharged from our hospital at 32 days of age.
Discussion
In normal newborns, the plasma ammonia concentration is less than 100 mmol l À1 . Levels above 200 mmol l À1 suggest an inborn error of metabolism. 3 Besides disorders due to inborn errors in the urea cycle enzymes, organic acidemia, severe hepatic failure, the presence of a portosystemic shunt, a hyperactive mutation of glutamate dehydroxygenase, a severe infection or asphyxia can also cause hyperammonemia. 3 In contrast, MPHD has been rarely recognized as a cause of hyperammonemia. Only one case report in English has so far been published about hyperammonemia associated with neonatal hypopituitarism. Table 1 ) have also been reported in Japanese journals, and there was another case presenting transient hyperammonemia with neonatal MPHD in our hospital (Patient 5 in Table 1 ). All cases were full-term newborns, and their birth weight was appropriate for their gestational age. None of the cases had infections or asphyxia. All cases but Patient 4 were evaluated for the plasma amino-acid and urine organic-acid metabolites, and urea cycle defects, organic academia or inborn errors of amino-acid metabolism were ruled out. All cases developed the first clinical symptoms, such as seizures, apnea or failure to thrive within the first day of life. All cases had both central hypothyroidism and hypoadrenocorticism, and they were diagnosed by clinical manifestations and brain magnetic resonance imaging with endocrinological examination. Patient 1 showed the highest value of plasma ammonia, and died at 33 days of age, despite of the use of hormone replacement therapy. The mechanism underlying the hyperammonemia caused by MPHD in neonates is unknown. Bhoyar et al.
2 speculated that the high ammonia level could be a result of neonatal hepatitis associated with congenital hypopituitarism. The authors who reported Patient 2 speculated that hyperammonemia observed in their patient might have resulted from cholestatic hepatitis by central hypothyroidism because the infant's ammonia level had normalized after hormone replacement therapy. Our patient, however, did not have any liver dysfunction when hyperammonemia was detected, and the plasma ammonia level normalized before hormone replacement was administered. Therefore, neonatal cholestatic hepatitis might not be an essential cause of hyperammonemia. Another possibility is that generalized seizure by hypoglycemia might additionally affect the elevation of ammonia in peripheral blood, because the previous reports in adult and pediatric populations demonstrated that patients showed transient hyperammonemia (142 to 231 mmol l À1 (ref. 4) 44 to 447 mmol l À1 (ref. 5) respectively) after a generalized seizure. In conclusion, the plasma ammonia level may be significantly elevated in some infants with MPHD without any inborn errors of metabolism. When a newborn presents with hyperammonemia with hypoglycemia during the first few days of life, MPHD should therefore be considered in the differential diagnosis. Early diagnosis and intervention can lead to a significant improvement in the outcome for these patients.
